University of Minnesota, Minneapolis, MN, United States of America.
Laureate Institute for Brain Research, Tulsa, OK, United States of America.
PLoS One. 2022 Feb 4;17(2):e0263558. doi: 10.1371/journal.pone.0263558. eCollection 2022.
Mal de Débarquement Syndrome (MdDS) is a medically refractory neurotological disorder characterized by persistent oscillating vertigo that follows a period of entrainment to oscillating motion such as experienced during sea or air travel. Fronto-occipital hypersynchrony may correlate with MdDS symptom severity.
Individuals with treatment refractory MdDS lasting at least 6 months received single administrations of three fronto-occipital transcranial alternating current stimulation (tACS) protocols in an "n-of-1" double-blind randomized design: alpha frequency anti-phase, alpha-frequency in-phase, and gamma frequency control. Baseline assessments were made on Day 1. The treatment protocol that led to the most acute reduction in symptoms during a test session on Day 2 was administered for 10-12 stacked sessions given on Days 3 through 5 (20-minutes at 2-4mA). Pre to post symptom changes were assessed on Day 1 and Day 5. Participants who could clearly choose a preferred protocol on Day 2 did better on Day 5 than those who could not make a short-term determination on Day 2 and either chose a protocol based on minimized side effects or were randomized to one of the three protocols. In addition, weekly symptom assessments were made for four baseline and seven post stimulation points for the Dizziness Handicap Inventory (DHI), MdDS Balance Rating Scale (MBRS), and Hospital Anxiety and Depression Scale (HADS).
Of 24 participants, 13 chose anti-phase, 7 chose in-phase, and 4 chose control stimulation. Compared to baseline, 10/24 completers noted ≥ 25% reduction, 5/24 ≥50% reduction, and 2/24 ≥75% reduction in oscillating vertigo intensity from Day 1 to Day 5. Stimulating at a frequency slightly higher than the individual alpha frequency (IAF) was better than stimulating at exactly the IAF, and slightly better than stimulating with a strategy of standardized stimulation at 10Hz. A one-way repeated measures ANOVA of weekly DHI, MBRS, and HADS measurements showed significant reductions immediately after treatment with improvement increasing through post-treatment week 6.
Fronto-occipital tACS may be effective in reducing the oscillating vertigo of MdDS and serve as a portable neuromodulation alternative for longer-term treatment. Stimulation frequency relative to the IAF may be important in determining the optimum treatment protocol [ClinicalTrials.gov study NCT02540616. https://clinicaltrials.gov/ct2/show/NCT02540616].
晕动病后综合征(MdDS)是一种医学难治性神经耳科疾病,其特征为持续的摆动性眩晕,这种眩晕是在经历过如航海或航空旅行中经历的摆动运动后产生的。额枕部超同步可能与 MdDS 症状严重程度相关。
患有至少 6 个月难治性 MdDS 的个体接受了三种额枕部经颅交流电刺激(tACS)方案的单次给药,采用“n-of-1”双盲随机设计:α 频率反相、α 频率同相和γ 频率对照。在第 1 天进行基线评估。在第 2 天的测试中,导致症状急性减轻的治疗方案在第 3 天至第 5 天的 10-12 个堆叠疗程中给予(2-4mA,20 分钟)。在第 1 天和第 5 天评估治疗前后的症状变化。在第 2 天能够清楚选择首选方案的参与者在第 5 天的表现优于那些在第 2 天无法做出短期判断的参与者,并且要么选择基于最小副作用的方案,要么随机分配到三个方案之一。此外,在基线和刺激后的 4 个基线和 7 个点进行了 Dizziness Handicap Inventory(DHI)、MdDS Balance Rating Scale(MBRS)和 Hospital Anxiety and Depression Scale(HADS)的每周症状评估。
在 24 名参与者中,有 13 名选择了反相刺激,7 名选择了同相刺激,4 名选择了对照刺激。与基线相比,24 名完成者中有 10 名(42%)注意到摆动性眩晕强度至少降低 25%,5 名(21%)降低 50%,2 名(8%)降低 75%,从第 1 天到第 5 天。刺激频率略高于个体 alpha 频率(IAF)比刺激 IAF 更好,略优于以 10Hz 为标准的刺激策略。每周 DHI、MBRS 和 HADS 测量的单向重复测量方差分析显示,治疗后立即出现显著减少,并且治疗后第 6 周逐渐增加。
额枕部 tACS 可能有效减轻 MdDS 的摆动性眩晕,并可作为一种便携式神经调节替代方法用于长期治疗。刺激频率相对于 IAF 可能是确定最佳治疗方案的重要因素[ClinicalTrials.gov 研究 NCT02540616。https://clinicaltrials.gov/ct2/show/NCT02540616]。